Medical News

---

• IGF axis proteins linked to diabetes risk
• Bevacizumab fails to improve elderly NSCLC survival
• Greater progression-free survival seen with maintenance gefitinib therapy
• Afatinib shows promise in EGFR-TKI-resistant lung cancer patients
• Lung cancer patients with <i>EGFR</i> mutations respond to afatinib
• Bevacizumab fails to improve elderly NSCLC survival
• Greater progression-free survival seen with maintenance gefitinib therapy
• Afatinib shows promise in EGFR-TKI-resistant lung cancer patients
• Lung cancer patients with <i>EGFR</i> mutations respond to afatinib
• Possible link between <i>Chlamydophila psittaci</i> infection and psoriasis uncovered
• Bevacizumab fails to improve elderly NSCLC survival
• Greater progression-free survival seen with maintenance gefitinib therapy
• Afatinib shows promise in EGFR-TKI-resistant lung cancer patients

IGF axis proteins linked to diabetes risk Posted: 10 May 2012 05:00 PM PDT Measuring circulating levels of free insulin-like growth factor-1 and three IGF binding proteins could help physicians determine incident diabetes risk, show findings from a US study.

Bevacizumab fails to improve elderly NSCLC survival Posted: 10 May 2012 05:00 PM PDT Results indicate that the addition of bevacizumab to carboplatin and paclitaxel chemotherapy does not increase survival rates in older patients with non-small-cell lung cancer.

Greater progression-free survival seen with maintenance gefitinib therapy Posted: 10 May 2012 05:00 PM PDT Treatment with gefitinib improves progression-free survival in patients with locally advanced or metastatic non-small-cell lung cancer who have previously responded to platinum-based chemotherapy, research suggests.

Afatinib shows promise in EGFR-TKI-resistant lung cancer patients Posted: 10 May 2012 05:00 PM PDT Treatment with afatinib could improve progression-free survival and health-related quality of life – but not overall survival – in advanced, metastatic non-small-cell lung cancer patients, compared with placebo, show study results.

Lung cancer patients with <i>EGFR</i> mutations respond to afatinib Posted: 10 May 2012 05:00 PM PDT Lung cancer patients with epidermal growth factor receptor mutations have promising outcomes – including a partial or complete response and acceptable levels of adverse events – after treatment with afatinib, say researchers.

Bevacizumab fails to improve elderly NSCLC survival Posted: 10 May 2012 05:00 PM PDT Results indicate that the addition of bevacizumab to carboplatin and paclitaxel chemotherapy does not increase survival rates in older patients with non-small-cell lung cancer.

Greater progression-free survival seen with maintenance gefitinib therapy Posted: 10 May 2012 05:00 PM PDT Treatment with gefitinib improves progression-free survival in patients with locally advanced or metastatic non-small-cell lung cancer who have previously responded to platinum-based chemotherapy, research suggests.

Afatinib shows promise in EGFR-TKI-resistant lung cancer patients Posted: 10 May 2012 05:00 PM PDT Treatment with afatinib could improve progression-free survival and health-related quality of life – but not overall survival – in advanced, metastatic non-small-cell lung cancer patients, compared with placebo, show study results.

Lung cancer patients with <i>EGFR</i> mutations respond to afatinib Posted: 10 May 2012 05:00 PM PDT Lung cancer patients with epidermal growth factor receptor mutations have promising outcomes – including a partial or complete response and acceptable levels of adverse events – after treatment with afatinib, say researchers.

Possible link between <i>Chlamydophila psittaci</i> infection and psoriasis uncovered Posted: 10 May 2012 05:00 PM PDT Subclinical infection with Chlamydophila psittaci may increase a person's risk for psoriasis, say researchers.

Bevacizumab fails to improve elderly NSCLC survival Posted: 10 May 2012 05:00 PM PDT Results indicate that the addition of bevacizumab to carboplatin and paclitaxel chemotherapy does not increase survival rates in older patients with non-small-cell lung cancer.

Greater progression-free survival seen with maintenance gefitinib therapy Posted: 10 May 2012 05:00 PM PDT Treatment with gefitinib improves progression-free survival in patients with locally advanced or metastatic non-small-cell lung cancer who have previously responded to platinum-based chemotherapy, research suggests.

Afatinib shows promise in EGFR-TKI-resistant lung cancer patients Posted: 10 May 2012 05:00 PM PDT Treatment with afatinib could improve progression-free survival and health-related quality of life – but not overall survival – in advanced, metastatic non-small-cell lung cancer patients, compared with placebo, show study results.

You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610